Resonance Health Ltd

As of June 30, 2024, Resonance Health Ltd carries a market capitalization of 26.37M, placing it among publicly traded companies globally. Its enterprise value stands at 19.76M, reflecting the total theoretical takeover cost after accounting for cash holdings and debt obligations.

As of June 30, 2024, Resonance Health Ltd has 446.89M shares outstanding.

As of June 30, 2024, Resonance Health Ltd trades at a trailing price-to-earnings ratio of 158.93. The price-to-sales ratio is 3.13, and the price-to-book ratio stands at 2.41.

These figures are as of June 30, 2024. The EV/Sales ratio of 2.30 reflects the premium investors pay for the company's revenue stream, a useful check when earnings are depressed or negative. These enterprise value multiples are built on an enterprise value of 19.76M versus a market cap of 26.37M, with the gap driven by net debt and cash on the balance sheet.

As of June 30, 2024, Resonance Health Ltd maintains a current ratio of 2.07, meaning it holds 2.1x the short-term assets needed to cover near-term liabilities.

Over the twelve months ended June 30, 2024, Resonance Health Ltd posted a return on equity (ROE) of 1.62, showing how much profit the company earns on every dollar of shareholder capital. Return on assets (ROA) stands at 0.95, measuring how efficiently the asset base is converted into earnings.

Over the twelve months ended June 30, 2024, Resonance Health Ltd recorded an income tax benefit of -796,192.00 rather than an expense, typically from losses, carryforwards, or the release of a tax provision. The company reported a pretax loss of -626,889.00 and 169,303.00 in bottom-line net income, so the effective tax rate carries little signal until profitability returns.

As of the close on October 22, 2026, Resonance Health Ltd's stock has gained approximately 67.35% over the past 52 weeks. The 50-day moving average sits at 0.07, while the 200-day moving average is 0.05.

Over the twelve months ended June 30, 2024, Resonance Health Ltd generated 8.59M in revenue and converted that into 169,303.00 in net income, yielding earnings per share of 0.00. EBITDA reached -381,527.00, while operating income came in at -879,473.00.

As of June 30, 2024, Resonance Health Ltd holds 10.31M in cash and equivalents against 3.70M in total debt, resulting in a net debt position of -7.13M. Total book value stands at 10.93M, with working capital of 6.59M providing operational flexibility.

These figures cover the twelve months ended June 30, 2024.

These figures cover the twelve months ended June 30, 2024. The operating margin of -10.24 and net profit margin of 1.97 provide insight into operational efficiency.

These figures cover the twelve months ended June 30, 2024. Total shareholder yield is negative at -11.41, meaning Resonance Health Ltd raised more capital through share issuance and new debt than it returned via dividends and buybacks.

Resonance Health Ltd's most recent stock split took place on April 28, 2014 with a 262:265 split ratio.

As of June 30, 2024, Resonance Health Ltd has an Altman Z-Score of -3.98, below the 3.0 threshold that indicates strong financial health and minimal bankruptcy risk.